Nature‘s Molecular Psychiatry published the analysis.
HCQ is a disease-modifying anti-rheumatic drug (DMARD) that can reduce pain and swelling associated with arthritis. It is also used to treat malaria and lupus.
The drug received substantial attention in the early days of the pandemic after it was hailed as a potential therapeutic agent for COVID-19 but later fell out of favor. The U.S. government eventually concluded that it does not benefit hospitalized COVID patients.
In the Molecular Psychiatry analysis, researchers concluded that the JAK/STAT pathway is a potential Alzheimer’s target. H…